Clinical Trial Update: A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating fulvestrant in breast ductal carcinoma in situ was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Ductal Carcinoma in Situ

Drugs mentioned

• Fulvestrant (Faslodex) (fulvestrant)

Snippet

Sponsor: University of Southern California | Conditions: Breast Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2012-12-06